Amneal Pharmaceuticals Gets FDA Approval for Injectable Tumor Treatment
June 14 2023 - 8:59AM
Dow Jones News
By Will Feuer
Amneal Pharmaceuticals said it has received 505(b)(2) New Drug
Application approval from the U.S. Food and Drug Administration for
Pemrydi RTU, a ready-to-use presentation of pemetrexed, a type of
chemotherapy, for injection.
The injectable doesn't require reconstitution, dilution or
refrigeration. It will be available in three vial sizes, the
company said. Amneal Pharmaceuticals said it expects to launch the
product in the first quarter of 2024.
Shares rose 4.7% to $2.70 in premarket trading.
Write to Will Feuer at Will.Feuer@wsj.com
(END) Dow Jones Newswires
June 14, 2023 08:44 ET (12:44 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Amneal Pharmaceuticals (NYSE:AMRX)
Historical Stock Chart
From Apr 2024 to May 2024
Amneal Pharmaceuticals (NYSE:AMRX)
Historical Stock Chart
From May 2023 to May 2024
